Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.
Dan Zandberg, MD
Advertisement
Articles by Dan Zandberg, MD
Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.
Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.
Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Advertisement
Latest Updated Articles
Dr. Zandberg on Durvalumab Trial in Head and Neck CancerPublished: September 22nd 2017 | Updated:
Dr. Zandberg on the Role of Durvalumab in Head and Neck CancerPublished: October 14th 2017 | Updated:
- Dr. Zandberg on the Role of Immunotherapy in Head and Neck Cancer
Published: October 18th 2017 | Updated:
Dr. Zandberg on Biomarker Development in Head and Neck CancerPublished: October 18th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5